199 related articles for article (PubMed ID: 36222298)
21. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
Gao BB; Wang SX
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
[TBL] [Abstract][Full Text] [Related]
22. LINC02389/miR-7-5p Regulated Cisplatin Resistance of Non-Small-Cell Lung Cancer via Promoting Oxidative Stress.
Ma P; Han W; Meng C; Tan X; Liu P; Dong L
Anal Cell Pathol (Amst); 2022; 2022():6100176. PubMed ID: 36311891
[TBL] [Abstract][Full Text] [Related]
23. LINC01140 inhibits nonsmall cell lung cancer progression and cisplatin resistance through the miR-4742-5p/TACC1 axis.
Wang Y; Li M; Zhang L; Chen Y; Ha M
J Biochem Mol Toxicol; 2022 Jul; 36(7):e23048. PubMed ID: 35307914
[TBL] [Abstract][Full Text] [Related]
24. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S
Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930
[TBL] [Abstract][Full Text] [Related]
25. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis.
Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X
Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110
[TBL] [Abstract][Full Text] [Related]
26. The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells.
Guo J; Jin D; Wu Y; Yang L; Du J; Gong K; Chen W; Dai J; Miao S; Xi S
EBioMedicine; 2018 Sep; 35():204-221. PubMed ID: 30146342
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of lncRNA EGFR‑AS1 is associated with a poor prognosis and promotes chemotherapy resistance in non‑small cell lung cancer.
Xu YH; Tu JR; Zhao TT; Xie SG; Tang SB
Int J Oncol; 2019 Jan; 54(1):295-305. PubMed ID: 30431074
[TBL] [Abstract][Full Text] [Related]
29. Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.
Tung MC; Lin PL; Cheng YW; Wu DW; Yeh SD; Chen CY; Lee H
Oncotarget; 2016 May; 7(22):32362-74. PubMed ID: 27083050
[TBL] [Abstract][Full Text] [Related]
30. Circ_0011292 knockdown mitigates progression and drug resistance in PTX-resistant non-small-cell lung cancer cells by regulating miR-433-3p/CHEK1 axis.
Jin M; Zhang F; Li Q; Xu R; Liu Y; Zhang Y
Thorac Cancer; 2022 May; 13(9):1276-1288. PubMed ID: 35348291
[TBL] [Abstract][Full Text] [Related]
31. KRAS Inhibitor Resistance in
Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
[TBL] [Abstract][Full Text] [Related]
32. Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling.
Wang N; Song L; Xu Y; Zhang L; Wu Y; Guo J; Ji W; Li L; Zhao J; Zhang X; Zhan L
EBioMedicine; 2019 Sep; 47():65-77. PubMed ID: 31495720
[TBL] [Abstract][Full Text] [Related]
33. CDKN1A upregulation and cisplatin‑pemetrexed resistance in non‑small cell lung cancer cells.
Zamagni A; Pasini A; Pirini F; Ravaioli S; Giordano E; Tesei A; Calistri D; Ulivi P; Fabbri F; Foca F; Delmonte A; Molinari C
Int J Oncol; 2020 Jun; 56(6):1574-1584. PubMed ID: 32236605
[TBL] [Abstract][Full Text] [Related]
34. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
[TBL] [Abstract][Full Text] [Related]
35. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
36. Knockdown of lncRNA ANRIL inhibits the development of cisplatin resistance by upregulating miR‑98 in lung cancer cells.
Wang X; Zhang G; Cheng Z; Dai L; Jia L; Jing X; Wang H; Zhang R; Liu M; Jiang T; Yang Y; Yang M
Oncol Rep; 2020 Sep; 44(3):1025-1036. PubMed ID: 32705261
[TBL] [Abstract][Full Text] [Related]
37. A novel cancer-germline gene DAZL promotes progression and cisplatin resistance of non-small cell lung cancer by upregulating JAK2 and MCM8.
Zhou L; Le MNU; Du Y; Chen X; Jin M; Xiang H; Xia LE; Zhou J; He J; Ning Y
Gene; 2024 Jul; 916():148449. PubMed ID: 38588931
[TBL] [Abstract][Full Text] [Related]
38. Circ_0072088 knockdown contributes to cisplatin sensitivity and inhibits tumor progression by miR-944/LASP1 axis in non-small cell lung cancer.
Zhang L; Wu Y; Hou C; Li F
J Gene Med; 2022 May; 24(5):e3414. PubMed ID: 35106879
[TBL] [Abstract][Full Text] [Related]
39. Circ_0000079 Decoys the RNA-Binding Protein FXR1 to Interrupt Formation of the FXR1/PRCKI Complex and Decline Their Mediated Cell Invasion and Drug Resistance in NSCLC.
Chen C; Zhang M; Zhang Y
Cell Transplant; 2020; 29():963689720961070. PubMed ID: 32951448
[TBL] [Abstract][Full Text] [Related]
40. PLAU promotes growth and attenuates cisplatin chemosensitivity in ARID1A-depleted non-small cell lung cancer through interaction with TM4SF1.
Zheng Y; Zhang L; Zhang K; Wu S; Wang C; Huang R; Liao H
Biol Direct; 2024 Jan; 19(1):7. PubMed ID: 38229120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
